Hello, I am Jo Frowde, ISN Guide to Habeo Cell Therapy. Habeo Cell Therapy by Cytori Therapeutics is an experimental treatment in clinical trial for diffuse scleroderma hand involvement. See Disclaimer.
Habeo Cell Therapy by Cytori Therapeutics is an experimental treatment in clinical trial for scleroderma hand involvement. It entails removing fat cells from the patient, harvesting the stem cells, and reintroducing them. The Phase III trials showed some benefit, particularly for hand involvement in diffuse cutaneous scleroderma patients who have sclerodactyly (hands hardened by scleroderma.) (Also see: What is Scleroderma?, Diffuse Scleroderma, and Sclerodactyly)
Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress. Cytori Therapeutics, Inc. presented data from the U.S. 88 patient, 19 center, randomized, double blind, placebo-controlled STAR clinical trial of Cytori Cell Therapy™ (Habeo™) for the treatment of impaired hand function in patients with systemic sclerosis (SSc). Globe Newswire, 02/15/2018.
American Medical Association Adding Cytori’s Cell–Based Therapy for Scleroderma Hand Problems to Key Database. The American Medical Association is adding descriptions of Cytori Therapeutics’ cell–based therapy for scleroderma of the hands to its authoritative database of medical procedures, services and technology. Scleroderma News, 07/11/2017.
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial. Cytori Therapeutics, Inc. today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subject’s 48 week visit was conducted earlier this week. Globe Newswire, 05/23/2017.
Cytori’s Managed Access Program. Cytori’s Managed Access Program in select countries across Europe, the Middle East, and Africa is intended to provide patients with hand impairment due to scleroderma early access to ECCS-50 therapy. Cytori Theraputics Inc.
Cytori Therapeutics Receives Approval for Scleroderma Study in France. Per the study protocol, 13 patients will receive an injection of their own adipose-derived stem and regenerative cells (ADRCs) into the affected areas of their fingers. StreetInsider.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: